ArticleLupus science & medicine2026
Discordance between disease activity and long-term outcomes in DNASE1L3 deficiency: a multicentre longitudinal cohort study.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDNASE1L3 deficiency is a rare monogenic cause of early-onset SLE and hypocomplementaemic urticarial vasculitis syndrome (HUVS). While early disease manifestations are increasingly recognised, longitudinal data extending into adulthood remain scarce. In this study, we described the long-term disease trajectory, damage accrual and mortality across the largest DNASE1L3 deficiency cohort reported to date.
methodsWe conducted a multicentre retrospective longitudinal cohort study of patients with genetically confirmed DNASE1L3 deficiency followed at paediatric rheumatology tertiary centres in Oman and the UAE. Primary outcomes included damage accrual, flare rates, hospitalisation frequency, serious infections and mortality. Longitudinal comparisons were made between the last paediatric assessment and most recent adult follow-up.
results57 patients from 22 families were enrolled, most carrying the homozygous DNASE1L3 c.643delT loss of function variant. Median age at diagnosis was 5 (1.75-13) years and median disease duration was 9 (1-22) years. Initial phenotypes comprised of SLE in 36 patients (63%) and HUVS in 21 (37%). Despite a significant reduction in disease activity (SLE Disease Activity Index scores) over the follow-up period (9 vs 4; p<0.001), this was not accompanied by clear improvement in long-term outcomes. Mean Systemic Lupus Interntational Collaborating Clinics (SLICC)/American College of Rheumatology Damage Index increased numerically from 0.37±0.85 to 0.72±1.17; p=0.295. The proportion with lupus nephritis increased from 34% to 46% (p=0.07) and pulmonary involvement from 3.7% versus 11% at follow-up (p=0.289), osteoporosis increased from 23% to 41% (p=0.065) and mortality was numerically higher following transition, increasing from 8.8% to 13.5% (p=0.125).
conclusionsIn the largest DNASE1L3 deficiency cohort, reduction in clinical disease activity does not prevent progressive organ damage. These findings suggest that apparent disease quiescence may mask ongoing subclinical injury, underscoring the need for sustained long-term surveillance and optimised transitional care strategies. However, the findings should be interpreted with caution in light of the small sample size in this ultra-rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.